Key facts
- Pictor’s last known valuation is $85.6M (Dec 2022).
- It has raised $22.6M.
- Notable investors include K1W1, New Zealand Growth Capital Partners, Arc Angels, Aspire NZ Seed Fund, Callaghan Innovation — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Pictor
- ·The full record, as it builds
Funding rounds
No funding rounds for Pictor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pictor
Developer of a proteomics platform designed to detect multiple biomarkers simultaneously for comprehensive biological analysis. The company offers an AI-integrated, end-to-end workflow, enabling clinical trials, diagnostics manufacturers, clinical labs, drug developers, and veterinary clinics to gain broader insights with reduced cost and complexity
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2005
- Employees
- 25
- Website
- pictordx.com/
- Ownership
- Privately Held (backing)
Pictor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pictor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pictor in its N-PORT filings yet. We sweep new filings monthly.